Aardvark Therapeutics AARD
NASDAQ AARD
$4.99 -0.28 (-5.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Aardvark Therapeutics (AARD) Cash & Equivalents (2024 - 2026)

Updated

Aardvark Therapeutics' Cash & Equivalents came in at $73.85 million for Q2 2026, up 184.1% from $26 million a year earlier and up 18.3% from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Cash & Equivalents (2024 - 2026) Analysis & Trends

At the end of FY2025, Aardvark Therapeutics' Cash & Equivalents was $47.05 million, down 23.7% from FY2024.

  • Going back by year, Cash & Equivalents was $61.64 million in FY2024.
  • Business Quant data shows AARD's Cash & Equivalents at $62.44 million (Q1 2026), $47.05 million (Q4 2025) and $39.29 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 20.42 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 6.57 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 4.89 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 3.18 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 976.00 Mn
10 Aardvark Therapeutics 115.33 Mn 41.43 Mn - 73.85 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 73.85 Mn
Mar 31, 2026 62.44 Mn
Dec 31, 2025 47.05 Mn
Sep 30, 2025 39.29 Mn
Jun 30, 2025 26.00 Mn
Mar 31, 2025 26.50 Mn
Dec 31, 2024 61.64 Mn
API Access

Aardvark Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AARD&period=max&api_key=YOUR_API_KEY